Publication details
Diabetes s kardiovaskulárním onemocněním - co s tím?
| Title in English | Diabetes and Cardiovascular Disease - what with this? |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Acta medicinae |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | diabetes mellitus 2. type; CV risk; empagliflozine; heart failure; clinical studies |
| Description | Diabetes increases risk of cardiovascular disease, especialy heart failure, hi the EMPA-REG OUTCOME trial, empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced the risk of major adverse cardiovascular events in patients with type 2 diabetes at high risk for cardiovascular events, including heart failure. |